10 results about "Clindamycin" patented technology

The present invention belongs to the field of biotechnology, and specifically relates to the use of the CD630_27900 gene in reducing the tolerance of Clostridium difficile. Knocking out the CD630_27900 gene can reduce the tolerance of Clostridium difficile to acidic environments and antibiotics and reduce its cytotoxicity; the sequence of the CD630_27900 gene is shown in SEQ ID NO.1; the antibiotics include ampicillin, metronidazole, amoxicillin, vancomycin, norfloxacin, cefoxitin, clindamycin and kanamycin. The research results of the present invention suggest that the CD630_27900 gene can be used as a target for inhibiting the drug resistance and reducing the toxicity of Clostridium difficile, providing a new idea for the treatment of Clostridium difficile infection (CDI).

This invention discloses the application of L-lysine in improving the sensitivity of Vibrio alginolyticus to clindamycin. This invention discovers that the combined use of L-lysine and clindamycin can significantly increase reactive oxygen species within Vibrio alginolyticus, thereby increasing the amount of clindamycin entering the bacteria and ultimately leading to bacterial death. Therefore, L-lysine can improve bacterial sensitivity to clindamycin, thus overcoming the problem of bacterial resistance. The small molecule metabolite provided by this invention, when used in combination with clindamycin, can significantly enhance the bactericidal effect of clindamycin, exhibiting better efficacy, higher safety, and greater operability compared to existing methods that use clindamycin alone as an antibacterial drug.

The invention belongs to the technical field of biology, and particularly relates to a bifidobacterium longum subsp. Longum FMBL B241768LS, a microbial inoculum and application of the microbial inoculum in hypoglycemic products, the bifidobacterium longum subsp. Longum FMBL B241768LS is preserved in China Center for Type Culture Collection on October 14, 2024, and the preservation number is CCTCC NO: M 20242173; the inhibitory activity of the compound on dipeptidyl peptidase IV is as high as 79.17%; the compound has a relatively good inhibition effect on the activity of alpha-glucosidase and alpha-amylase; the compound shows drug resistance to ciprofloxacin, ampicillin, penicillin G, clindamycin, kanamycin and polymyxin B; a good inhibition effect is achieved on pathogenic bacteria; the strain can be used for preparing medicines, fermented foods, health-care products and food additives for reducing blood sugar and inhibiting pathogenic bacteria, and has a wide application prospect.

The invention provides a pH response type porous modified Japanese banana core fiber multifunctional composite medical dressing and a preparation method thereof.The dressing takes Japanese banana core fibers with low crystallinity and high hydroxyl exposure degree as a base material, a porous network is formed through carboxymethylation modification, chitosan, baicalin and clindamycin are loaded, and the pH response type porous modified Japanese banana core fiber multifunctional composite medical dressing is obtained. The preparation method comprises the following steps: pretreating musa basjoo core fibers with an H2O2 solution containing disodium ethylene diamine tetraacetate to obtain short fibers, proportionally mixing the short fibers, chitosan and baicalin, adding the obtained mixture into a dissolution system, carrying out electrospinning to obtain a nanofiber membrane, carrying out freeze drying to construct a porous structure, and carrying out carboxymethylation modification and pH-responsive drug loading to obtain the antibacterial hydrogel. And finally, compounding collagen, rolling and sterilizing. The pH response type porous modified banana core fiber multifunctional composite medical dressing has the functions of pH sensitive drug release, efficient antibiosis, rapid hemostasis, wound repair promotion and the like, and high-valued utilization of waste banana core fibers is achieved.

Described herein is a method of predicting whether a bacterial vaginosis (BV) patient will respond to metronidazole treatment. The method comprises detecting a presence or absence of at least one of the Gardnerella vaginalis (Gv) genes selected from the group consisting of aruH, Ami, Cluster 1311, comEA, crcB, group_2326, group_2343, group_2558, group_2577, ssb, truB, yfeA, ykoD, and YneA, or an mRNA product, a protein product, or a metabolite thereof, in a sample from the patient. Also described herein is a method of treating, ameliorating, and / or preventing BV in a subject, which comprises administering to the subject an effective amount of metronidazole or an effective amount of clindamycin based on a prediction of whether the subject responds well to metronidazole treatment.

The present invention provides the use of 5-fluoro-2'-deoxycytidine (CDP-3) in the preparation of antibacterial drugs. The present invention discovers for the first time that CDP-3 can inhibit the synthesis of bacterial phosphatidylglycerol by targeting bacterial phosphatidylglycerol phosphate synthase, and has antibacterial and broad-spectrum synergistic activities. Its MICs against Staphylococcus aureus and Streptococcus are 4 μg / mL and 8 μg / mL respectively, and the MIC 90 against methicillin-resistant Staphylococcus aureus is 8 μg / mL, and the MIC against hypervirulent Klebsiella pneumoniae is 16 μg / mL. In addition, CDP-3 can significantly enhance the antibacterial efficacy of antibiotics such as clindamycin, tilmicosin, tetracycline, florfenicol, gentamicin, chloramphenicol, rifampicin and ofloxacin against multi-drug resistant Gram-negative bacteria, and has broad-spectrum synergistic activity. Sub-inhibitory concentrations of CDP-3 can not only inhibit bacterial growth, but also reduce bacterial biofilm formation, and inhibit virulence and pathogenicity. CDP-3 not only increases the survival rate of Galleria mellonella infected with MRSA, but also shows excellent therapeutic efficacy against animal models infected with multi-drug resistant Gram-negative bacteria.

The present invention relates to a method for rapidly detecting lincomycin, clindamycin, erythromycin, clarithromycin and roxithromycin in water, belonging to the technical field of analytical detection. By means of specific fully automated on-line solid-phase extraction conditions in combination with specific high performance liquid chromatography-tandem mass spectrometry conditions, the present invention realizes sample enrichment, purification, separation and determination, and fully automatically analyzes lincomycin, clindamycin, erythromycin, clarithromycin and roxithromycin in water. The present invention realizes fully automated operation, and the total determination time only needs 11 min. The detection limit reaches the ng / L level. By washing the solid-phase extraction column with an ammonium bicarbonate aqueous solution, the problem of matrix effect commonly encountered in the analysis of complex matrix samples is overcome, meeting the requirements for ultra-trace detection of lincomycin, clindamycin, erythromycin, clarithromycin and roxithromycin in water.

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w / w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

The utility model relates to the technical field of purification devices, and discloses a clindamycin alcoholate purification device which comprises a base, a heating furnace, a condensation chamber and a water pump are fixedly installed at the top of the base, an air cylinder is fixedly installed at the top of the heating furnace, and a rack is fixedly installed at the telescopic end of the air cylinder. A heating plate is fixedly installed on the inner wall of the base, and a collecting pipe is fixedly assembled on the top of the base. When gas evaporated in the heating furnace reaches the interior of a condensation pipe through a conveying pipe, a water pump is started, condensate water in a condensation chamber is pumped out through the water pump, the condensate water is conveyed into a built-in pipe through a conveying pipe, and when the condensate water flows in the direction of a one-way circulation assembly along the built-in pipe, the condensate water flows in the one-way circulation assembly; at the moment, the built-in pipe is located in the condensation pipe, heat in the center position of steam in the condensation pipe is reduced, the temperature is reduced from the outside through condensate water outside the condensation pipe, and the overall condensation effect of the equipment is better.

The invention relates to the technical field of drug carriers, in particular to a drug carrier for suppurative arthritis and a preparation method of the drug carrier. The drug carrier comprises liquid metal nanoparticles, a mesoporous material shell layer coating the liquid metal nanoparticles and a hyaluronic acid modification layer coating the mesoporous material shell layer, wherein liquid metal is gallium (Ga), gallium-indium alloy (GaIn), or ternary or multicomponent alloy containing gallium, indium and tin; the mesoporous material is at least one of mesoporous silica, mesoporous titanium dioxide and mesoporous carbon. The drug carrier can be used for loading different types of therapeutic agents (drugs) such as antibiotics (such as clindamycin), anti-inflammatory drugs and anti-tumor drugs, and the therapeutic agents can enter mesopores of the mesoporous material shell layer.